Breast Cancer

What is the project scope?

Many people suffer from Triple Negative Breast Cancer (TNBC) and at present treatment fo this is not effective. However, it has recently been discovered that Checkpoint Kinase 1 (CHK1), a serine/threonine kinase activated in response to DNA damage, which can be caused by conventional chemotherapy treatments may play a role in this particular cancer. A number of CHK1 inhibitors are currently in clinical development. This includes CCT245737, a potent, selective, orally bioavailable inhibitor of CHK1

It is suggested that  CHK1 inhibition may be effective as a monotherapy for some patients. The plan is to test out this suggestion.

Working in conjunction with clinicians at the Kent Oncology Centre, a Multi Disciplinary Team with the School of Biosciences at the University of Kent has been formed to work through the following questions:

1  The TNBC cell lines available that are resistant to the cell lines available form the Resistant Cancer Cell Line (please see the project report on this) will be investigated.

2   Using the data available from that analysis, biomarkers will be identified.

3   These biomarkers will be validated against TNBC samples from the Kent Oncology Centre.

Following this work, it should be possible to decide whether there is scope for a more detailed project  to develop a useful drug to provide improved treatment of this form of breast cancer that currently affects some 90 patients through the Kent Oncology Centre at Maidstone each year.

What will this cost?

£15,000 will be spent over 3 years to provide the supplies that the PhD  candidate  working on this will require.  The salary and teaching costs of the PhD candidate will be met from a different source.

 

 


 

 

 

 


Breast Cancer
Webpage icon Breast Cancer